Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Stream Genomics Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, POHNERT, STEVEN C, who is responsible for 1 pending office action. The prosecution is focused within 1 distinct art unit.
The presence of the distinct examiner for the pending office action indicates a straightforward prosecution environment. The applicant can focus their strategy on the specific requirements of POHNERT, STEVEN C, which may streamline the path to allowance. This centralized approach reduces the administrative overhead associated with managing multiple examiners.
Operating within 1 distinct art unit further simplifies the process, as the company only needs to be familiar with the practices of a single USPTO division. This technical focus is consistent with the company's current workload of 1 pending office action. The legal team can leverage their understanding of the art unit to effectively address the examiner's concerns.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18803758 | Event-Based Sequencing of Nucleic Acids in Real Time | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18803758 | Event-Based Sequencing of Nucleic Acids in Real Time | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18803758 | Event-Based Sequencing of Nucleic Acids in Real Time | POHNERT, STEVEN C | 1683 | §101§103§112 | Final Rejection | — | Pending | Aug 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStream Genomics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Steven C Pohnert has the most, with 1 of Stream Genomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.